CN101809001B - 咪唑衍生物 - Google Patents

咪唑衍生物 Download PDF

Info

Publication number
CN101809001B
CN101809001B CN2008801089528A CN200880108952A CN101809001B CN 101809001 B CN101809001 B CN 101809001B CN 2008801089528 A CN2008801089528 A CN 2008801089528A CN 200880108952 A CN200880108952 A CN 200880108952A CN 101809001 B CN101809001 B CN 101809001B
Authority
CN
China
Prior art keywords
het
representes
phenyl
alk
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801089528A
Other languages
English (en)
Chinese (zh)
Other versions
CN101809001A (zh
Inventor
M·舒尔茨
K·席曼
G·博顿
A·布劳卡特
I·克贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN101809001A publication Critical patent/CN101809001A/zh
Application granted granted Critical
Publication of CN101809001B publication Critical patent/CN101809001B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008801089528A 2007-10-05 2008-09-09 咪唑衍生物 Expired - Fee Related CN101809001B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007047738.6 2007-10-05
DE102007047738A DE102007047738A1 (de) 2007-10-05 2007-10-05 Imidazolderivate
PCT/EP2008/007367 WO2009046804A1 (de) 2007-10-05 2008-09-09 Imidazolderivate

Publications (2)

Publication Number Publication Date
CN101809001A CN101809001A (zh) 2010-08-18
CN101809001B true CN101809001B (zh) 2012-12-12

Family

ID=40151186

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801089528A Expired - Fee Related CN101809001B (zh) 2007-10-05 2008-09-09 咪唑衍生物

Country Status (16)

Country Link
US (1) US20100249132A1 (enExample)
EP (1) EP2193122B1 (enExample)
JP (2) JP5725860B2 (enExample)
KR (1) KR20100075602A (enExample)
CN (1) CN101809001B (enExample)
AR (1) AR068659A1 (enExample)
AU (1) AU2008310117B2 (enExample)
BR (1) BRPI0817609A2 (enExample)
CA (1) CA2701568C (enExample)
DE (1) DE102007047738A1 (enExample)
EA (1) EA201000558A1 (enExample)
ES (1) ES2601139T3 (enExample)
IL (1) IL204683A (enExample)
MX (1) MX2010003368A (enExample)
WO (1) WO2009046804A1 (enExample)
ZA (1) ZA201003125B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009049211A1 (de) * 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
CA2825599C (en) 2011-02-01 2021-07-13 The Board Of Trustees Of The University Of Illinois 4-methyl-n-hydroxybenzamide compounds as histone deacetylase (hdac) inhibitors
ES2587856T3 (es) 2011-03-18 2016-10-27 Ono Pharmaceutical Co., Ltd. Derivado de tetrahidrocarbolina
ES2648901T3 (es) * 2011-10-28 2018-01-08 Inhibitaxin Limited Derivados de piridazina útiles en terapia
US9630945B2 (en) 2012-12-19 2017-04-25 Novartis Ag Autotaxin inhibitors
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
BR112016000779A8 (pt) 2013-07-18 2020-01-07 Novartis Ag inibidores de autotaxina que compreendem núcleo do ciclo de benzilamida de anel heteroaromático, seus usos, composição e combinação farmacêuticas
EP3022201A1 (en) * 2013-07-18 2016-05-25 Novartis AG Autotaxin inhibitors
ES2875899T3 (es) 2013-11-22 2021-11-11 Sabre Therapeutics Llc Compuestos inhibidores de autotaxina
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
JP6500092B2 (ja) * 2014-09-15 2019-04-10 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｔ型カルシウムチャンネルブロッカーとしてのトリアゾール化合物
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
JP6873919B2 (ja) 2015-05-27 2021-05-19 セイバー セラピューティクス エルエルシー オートタキシン阻害剤とその使用
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
US20230277490A1 (en) * 2020-07-31 2023-09-07 Cedars-Sinai Medical Center Glutamine as an anticancer therapy in solid tumors
EP4197596A1 (en) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Imidazole derivatives for the treatment and prophylaxis of infectious diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1258484A1 (en) * 2000-02-18 2002-11-20 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
CN1390222A (zh) * 1999-11-13 2003-01-08 默克专利股份有限公司 作为磷酸二酯酶ⅶ抑制剂的咪唑类化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
WO2000061186A1 (en) 1999-04-08 2000-10-19 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
FR2889190A1 (fr) * 2005-08-01 2007-02-02 Merck Sante Soc Par Actions Si Nouveaux derives d'imidazoles carboxamides comme inhibiteurs de fructose -1,6-biphosphatase et compositions pharmaceutiques les contenant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1390222A (zh) * 1999-11-13 2003-01-08 默克专利股份有限公司 作为磷酸二酯酶ⅶ抑制剂的咪唑类化合物
EP1258484A1 (en) * 2000-02-18 2002-11-20 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs

Also Published As

Publication number Publication date
EP2193122B1 (de) 2016-08-03
JP5997782B2 (ja) 2016-09-28
CN101809001A (zh) 2010-08-18
CA2701568C (en) 2017-06-06
BRPI0817609A2 (pt) 2015-03-31
AU2008310117A1 (en) 2009-04-16
AR068659A1 (es) 2009-11-25
IL204683A (en) 2014-08-31
JP2010540576A (ja) 2010-12-24
JP2015096544A (ja) 2015-05-21
ZA201003125B (en) 2011-05-25
ES2601139T3 (es) 2017-02-14
DE102007047738A1 (de) 2009-04-09
MX2010003368A (es) 2010-04-30
IL204683A0 (en) 2010-11-30
CA2701568A1 (en) 2009-04-16
JP5725860B2 (ja) 2015-05-27
AU2008310117B2 (en) 2013-07-18
WO2009046804A1 (de) 2009-04-16
US20100249132A1 (en) 2010-09-30
EA201000558A1 (ru) 2010-10-29
EP2193122A1 (de) 2010-06-09
KR20100075602A (ko) 2010-07-02

Similar Documents

Publication Publication Date Title
CN101809001B (zh) 咪唑衍生物
JP5847226B2 (ja) 腫瘍の治療のためのピペリジンおよびピペラジン誘導体
JP5843930B2 (ja) チアゾール誘導体
CN102822171B (zh) 作为自分泌运动因子抑制剂的苯并萘啶胺类
CN102227426A (zh) 作为自分泌运动因子抑制剂的苯并萘啶化合物
JP5767205B2 (ja) オートタキシン阻害剤としての複素環式化合物
JP4954973B2 (ja) 癌を治療するためのｉｇｆ−ｒ１阻害剤としての（１ｈ−インドール−７−イル）−（ピリミジン−２−イルアミノ）メタノン誘導体および関連化合物
JP2012532901A (ja) オートタキシン阻害剤としての複素環式化合物
CN102712604B (zh) 用于肿瘤治疗的亚砜衍生物
JP2007515419A (ja) ２−（ヘテロ）アリール置換テトラヒドロキノリン誘導体
KR20090130071A (ko) 테트라히드로퀴놀린 유도체 및 암 치료를 위한 이의 용도
JP5113035B2 (ja) フタラジノン
CN102292339B (zh) 作为MetAP-2抑制剂的新杂环化合物
HK1147488A (en) Imidazole derivatives
HK1147489A (en) Piperidine and piperazine derivatives for treating tumours
HK1147746A (en) Thiazol derivatives for treating cancer
HK1163673A (en) Benzonaphtyridine compounds used as inhibitors of autotaxin
HK1171221A (en) Heterocyclic compounds as autotaxin inhibitors
HK1167649A (en) Heterocyclic compounds as autotaxin inhibitors
HK1176931A (zh) 用於肿瘤治疗的亚碸衍生物
KR20060127002A (ko) 2-(헤테로)-아릴-치환 테트라하이드로퀴놀린 유도체

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1147488

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1147488

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121212

Termination date: 20180909